Novel Oral Anticoagulant Reversal Agent Tops AJPB Week in Review

Top news of the week from The American Journal of Pharmacy Benefits.

5. FDA OKs Treatment Combo for Advanced Renal Cell Carcinoma

Nivolumab plus low-dose ipilimumab combination is the first and only treatment to show significantly superior survival compared with sunitinib in intermediate- and poor-risk advanced renal cell carcinoma. Read more.

4. Congress, Medical Societies Address Approaches to Combat Opioid Crisis

Two different approaches to attack the opioid-fueled substance use disorder (SUD) crisis are on display this week. Read more.

3. Artificial Pancreas Improves Blood Sugar Control in Type 1 Diabetes

An artificial pancreas can improve blood sugar control for people with type 1 diabetes (T1D), according to a new study. Read more.

2. Childhood Factors May Contribute to COPD Risk

Childhood factors predisposed children to lung function decline and chronic obstructive pulmonary disease (COPD) as adults, according to 2 recent studies. Read more.

1. FDA Approves First Novel Oral Anticoagulant Reversal Agent

The approval is the first of its kind for a reversal agent of a novel oral anticoagulant (NOAC). Read more.